Chemotherapeutic drug combination

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9737566
SERIAL NO

15114854

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a chemotherapeutic drug combination containing heterodinuclear Cu (II)-Mn(II) complex. The objective of the present invention is to provide a drug combination, which will be actively used in chemotherapy, is anticarcinogenic and has no side effects, facilitates penetration into the cell, shows selectivity only for cancer cells and does not harm healthy cells, and is not toxic for the tissues and organs in the body, and which can prepared easily and provides a definitive and fast treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
YEDITEPE UNIVERSITESI34755 ISTANBUL

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Basak, Nese Malatya, TR 1 0
Dede, Bulent Isparta, TR 1 0
Demirci, Selami Istanbul, TR 8 22
Dogan, Aysegül Istanbul, TR 1 0
Sahin, Fikrettin Istanbul, TR 47 34

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 22, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 22, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00